The Role of the Gastrointestinal Microbiota in Parkinson’s Disease DOI Creative Commons
Maurizio Gabrielli, Lorenzo Zileri Dal Verme, Maria Assunta Zocco

et al.

Biomolecules, Journal Year: 2024, Volume and Issue: 15(1), P. 26 - 26

Published: Dec. 28, 2024

Background/Objectives: Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons leading to debilitating motor and non-motor symptoms. Beyond its well-known neurological features, emerging evidence underscores pivotal role gut–brain axis gastrointestinal microbiota in PD pathogenesis. Dysbiosis has been strongly linked associated with increased intestinal permeability, chronic inflammation, production neurotoxic metabolites that may exacerbate neuronal damage. Methods: This review delves into complex interplay between dysbiosis, shedding light on two peculiar subsets Helicobacter pylori infection small-intestinal bacterial overgrowth. These conditions not only contribute progression but also influence therapeutic responses such as L-dopa efficacy. Conclusions: The potential modulate gut through probiotics, prebiotics, synbiotics; fecal transplantation; antibiotics represents promising frontier for innovative treatments. Despite this potential, current limited small sample sizes methodological variability across studies. Rigorous, large-scale, randomized placebo-controlled trials standardized treatments terms composition, dosage, duration are urgently needed validate these findings pave way microbiota-based strategies management.

Language: Английский

The Effect of Gut Microbiota-Targeted Interventions on Neuroinflammation and Motor Function in Parkinson’s Disease Animal Models—A Systematic Review DOI Creative Commons
Paul-Ștefan Panaitescu,

Vlad Răzniceanu,

Ștefania-Maria Mocrei-Rebrean

et al.

Current Issues in Molecular Biology, Journal Year: 2024, Volume and Issue: 46(5), P. 3946 - 3974

Published: April 26, 2024

Gut microbiome-targeted interventions such as fecal transplant, prebiotics, probiotics, synbiotics, and antibiotic gut depletion are speculated to be of potential use in delaying the onset progression Parkinson’s disease by rebalancing microbiome context gut–brain axis. Our study aims organize recent findings regarding these animal models identify how they affect neuroinflammation motor outcomes. A systematic literature search was applied PubMed, Web Science, Embase, SCOPUS for non-dietary interventions. Studies that investigated gut-targeted using vivo murine PD follow dopaminergic cell loss, tests, neuroinflammatory markers outcomes were considered eligible. total 1335 studies identified databases, out which 29 found narrative systematization resulting data performed, effect direction represented. Quality assessment SYRCLE risk bias tool also performed. Out eligible studies, we a significant majority report intervention reduced loss (82.76%, 95% CI [64.23%, 94.15%]) produced induction model. Also, most reported reduction microglial (87.5%, [61.65%, 98.45%]) astrocytic activation (84,62%, [54.55%, 98.08%]) caused These results mirrored (96.4% [81.65%, 99.91%]) reporting an increase performance behavioral tests. limitation insufficient information assess specific causes bias. show can improve acute models. Further needed clarify if benefits transfer long-term pathogenesis disease, is not yet fully understood. The had no funding source, protocol registered PROSPERO database with ID number CRD42023461495.

Language: Английский

Citations

5
Antibiotic Cocktail Exacerbates Esomeprazole-Induced Intestinal Dysmotility While Ameliorating Gastric Dyspepsia in Mice DOI Creative Commons
Jing‐Hua Wang, Song-Yi Han, Kyung Jae Lee

et al.

Antibiotics, Journal Year: 2025, Volume and Issue: 14(5), P. 442 - 442

Published: April 27, 2025

Background/Objectives: Esomeprazole, a proton pump inhibitor (PPI), is commonly prescribed for gastric-acid-related disorders but has been associated with impaired gastrointestinal (GI) motility long-term use. However, the effect of concurrent antibiotic administration on this dysfunction remains unclear. Therefore, study aimed to investigate effects antibiotics esomeprazole-induced GI and explore underlying mechanisms in mouse model. Methods: Male C57BL/6 mice were orally administered esomeprazole (160 mg/kg) five times per week 4 weeks. Three days before initiating treatment, broad-spectrum cocktail (ABX) consisting ampicillin (1 g/kg), neomycin metronidazole vancomycin (0.5 g/kg) was provided drinking water maintained throughout experimental period. Mosapride (3 mg/kg), prokinetic agent, used as positive control. Results: Neither alone nor combination ABX affected body weight or food intake. Compared normal controls, treatment significantly delayed both intestinal transit gastric emptying. co-administration further pronounced time improved motility. The potential may involve interactions among H+/K+-ATPase, CYP3A11, hormones (secretin motilin), gut microbiome. Conclusions: Long-term use can impair motility, co-treatment exacerbates delay while paradoxically enhancing These findings highlight critical role microbiota suggest that should be approached caution, particularly when combined PPI therapy.

Language: Английский

Citations

0
Peroxisome Proliferator-Activated Receptors (PPARs) May Mediate the Neuroactive Effects of Probiotic Metabolites: An In Silico Approach DOI Open Access
Irving Parra, Alan Carrasco‐Carballo,

Victoria Palafox-Sánchez

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(10), P. 4507 - 4507

Published: May 9, 2025

It is well established that the gut-brain axis (GBA) a bidirectional communication between gut and brain. This axis, critical in maintaining overall homeostasis, regulated at neuronal, endocrine, immunological levels, all of which may be influenced by microbiota (GM). Therefore, dysbiosis or disruption GM have serious consequences including neuroinflammation due to overactivation immune system. Strategies reestablish integrity via use probiotics are being pursued as novel therapeutic intervention variety central peripheral diseases. The mechanisms leading efficacy probiotics, however, not fully evident. Here, we performed computational analysis on two major namely Lactobacillus Lacticaseibacillus rhamnosus GG (formerly named rhamnosus, L. GG) Bifidobacterium animalis spp. lactis (B. B. animalis) only shed some light their mechanism(s) action but also identify potential molecular targets for probiotics. Using PubMed web page BioCyc Database Collection platform specifically analyzed proteins affected metabolites these bacteria. Our results indicate peroxisome proliferator-activated receptors (PPARs), nuclear receptor involved regulation inflammation key mediators neuroactive effect

Language: Английский

Citations

0
Exploring the Frontiers of Neuroinflammation: New Horizons in Research and Treatment DOI Creative Commons
Giovanna Rigillo, Silvia Alboni

Current Issues in Molecular Biology, Journal Year: 2024, Volume and Issue: 46(10), P. 11665 - 11667

Published: Oct. 19, 2024

The Special Issue "

Language: Английский

Citations

1
The Role of the Gastrointestinal Microbiota in Parkinson’s Disease DOI Creative Commons
Maurizio Gabrielli, Lorenzo Zileri Dal Verme, Maria Assunta Zocco

et al.

Biomolecules, Journal Year: 2024, Volume and Issue: 15(1), P. 26 - 26

Published: Dec. 28, 2024

Background/Objectives: Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons leading to debilitating motor and non-motor symptoms. Beyond its well-known neurological features, emerging evidence underscores pivotal role gut–brain axis gastrointestinal microbiota in PD pathogenesis. Dysbiosis has been strongly linked associated with increased intestinal permeability, chronic inflammation, production neurotoxic metabolites that may exacerbate neuronal damage. Methods: This review delves into complex interplay between dysbiosis, shedding light on two peculiar subsets Helicobacter pylori infection small-intestinal bacterial overgrowth. These conditions not only contribute progression but also influence therapeutic responses such as L-dopa efficacy. Conclusions: The potential modulate gut through probiotics, prebiotics, synbiotics; fecal transplantation; antibiotics represents promising frontier for innovative treatments. Despite this potential, current limited small sample sizes methodological variability across studies. Rigorous, large-scale, randomized placebo-controlled trials standardized treatments terms composition, dosage, duration are urgently needed validate these findings pave way microbiota-based strategies management.

Language: Английский

Citations

0